Nuvectis Pharma Inc
NVCT
Get informed when a big investor buys or sells
+ FollowMarket Cap$625.2M
Close$
$1.45
92.4% downside
Current Fair Value
92.4% downsideOvervalued by 92.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $625.20 Million |
|---|---|
| Enterprise Value | $604.43 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.32 |
| Beta | -0.26 |
| Outstanding Shares | 23,475,989 |
Return
| Return on Equity | -333.35% |
|---|---|
| Return on Assets | -135.30% |
| Return on Invested Capital | -20.78% |
Valuation & Multiples
| P/E Ratio | -17.98 |
|---|---|
| PEG | -166.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -320.31 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 79.14% |
|---|---|
| Total Calls | 18,400▼ 80.61% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.30%▼ 0.13% |
|---|---|
| Total Invested | $34.94M▲ 9.08% |
| Investors Holding | 63▲ 12.00% |
ESG Score
No data